CJC-1295 vs Exenatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Exenatide

Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).

Full details →

Side-by-Side Comparison

Aspect	CJC-1295	Exenatide
Dose Range	1 mg–2 mg	5 mcg–10 mcg
Frequency	Less than daily	2x daily
Cycle Length	8–12 weeks	8–24 weeks
Route	subcutaneous	subcutaneous
Mechanism	CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.	Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety.
Typical Dosage	CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.	Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly.
Administration	Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.	Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe.
Side Effects	Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.	Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon).
Best For	Muscle Growth Fat Loss Sleep Quality	Fat Loss